Talquetamab Plus Daratumumab and Pomalidomide and Talquetamab Plus Daratumumab Prolong PFS Among Previously Treated Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 2, 2026 81 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy... October 9, 2020 EMA Recommends Granting a Marketing Authorisation for Nirogacestat July 3, 2025 Smoking addiction killed my grandfather – now it’s up to the... December 29, 2022 Looking back at a life-changing clinical trial September 16, 2022 Load more HOT NEWS When Prenatal DNA Tests Point to Cancer Pink Van Makes the Rounds Throughout Rural New Zealand to Offer... BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions What Should People With Cancer Know About Alkaline Water?
